What You Should Know:
– Nucs AI, a company that uses AI in precision medicine for the diagnosis and treatment of prostate cancer, today announces that it has closed a $3.5 million seed round of funding.
– The company will use the funding to further build out its platform and to support FDA clearance for its technology in the United States.
Nucs AI: Transforming Prostate Cancer Diagnosis and Treatment with Precision Medicine
Founded in 2023, Nucs AI is pioneering advancements in prostate cancer care through the integration of precision medicine and artificial intelligence (AI). With global prostate cancer cases projected to double between 2020 and 2040, the company aims to revolutionize patient outcomes by optimizing the use of prostate-specific membrane antigen (PSMA)-targeted imaging and therapeutics.
Nucs AI offers two AI-powered tools designed to enhance clinical decision-making:
- DeepPSMA: Employs discriminative AI for rapid, accurate detection, staging, and quantification of prostate cancer using PSMA-PET/CT imaging.
- SelectPSMA: Predicts individual patient response to PSMA-targeted radiopharmaceuticals, aiding in personalized cancer treatment strategies.
PSMA-PET/CT imaging has become the gold standard for detecting and staging prostate cancer, offering superior accuracy compared to conventional imaging. Complementing this, PSMA-targeted radiopharmaceuticals, such as 177Lu-PSMA-617 (Pluvicto), deliver internal radiation therapy directly to prostate cancer cells, slowing or reducing tumor growth.
The American Cancer Society reports that prostate cancer is the most commonly diagnosed cancer among men, with 1.5 million global cases annually and 299,000 new cases expected in the U.S. in 2024 alone. This underscores the urgent need for innovative tools to improve care delivery and outcomes.
Nucs AI’s mission is to equip clinicians with state-of-the-art resources to streamline workflows, enhance hospital capacity, and elevate patient care standards. As highlighted by Co-Founder and CEO Nijat Ahmadov, Nucs AI focuses on enabling personalized cancer care by identifying patients most likely to benefit from advanced PSMA-targeted therapies through its proprietary SelectPSMA technology.
By integrating AI with precision medicine, Nucs AI is setting new benchmarks in the diagnosis and treatment of prostate cancer, ensuring that patients receive tailored care for optimal clinical benefit.
